KR20250008764A - 안구 질환의 치료를 위한 보체 인자 i 투여 요법 - Google Patents

안구 질환의 치료를 위한 보체 인자 i 투여 요법 Download PDF

Info

Publication number
KR20250008764A
KR20250008764A KR1020247040205A KR20247040205A KR20250008764A KR 20250008764 A KR20250008764 A KR 20250008764A KR 1020247040205 A KR1020247040205 A KR 1020247040205A KR 20247040205 A KR20247040205 A KR 20247040205A KR 20250008764 A KR20250008764 A KR 20250008764A
Authority
KR
South Korea
Prior art keywords
cfi
per eye
weeks
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247040205A
Other languages
English (en)
Korean (ko)
Inventor
그랜트 이. 블루즈
나타샤 르모앙
톰 크누센
Original Assignee
버텍스 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버텍스 파마슈티칼스 인코포레이티드 filed Critical 버텍스 파마슈티칼스 인코포레이티드
Publication of KR20250008764A publication Critical patent/KR20250008764A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
KR1020247040205A 2022-05-04 2023-05-04 안구 질환의 치료를 위한 보체 인자 i 투여 요법 Pending KR20250008764A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338392P 2022-05-04 2022-05-04
US63/338,392 2022-05-04
PCT/US2023/066620 WO2023215840A1 (en) 2022-05-04 2023-05-04 Complement factor i dosing regimens for treating ocular diseases

Publications (1)

Publication Number Publication Date
KR20250008764A true KR20250008764A (ko) 2025-01-15

Family

ID=86760162

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040205A Pending KR20250008764A (ko) 2022-05-04 2023-05-04 안구 질환의 치료를 위한 보체 인자 i 투여 요법

Country Status (10)

Country Link
US (1) US20250177482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515091A (cg-RX-API-DMAC7.html)
KR (1) KR20250008764A (cg-RX-API-DMAC7.html)
CN (1) CN119698286A (cg-RX-API-DMAC7.html)
AU (1) AU2023265150A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251504A1 (cg-RX-API-DMAC7.html)
IL (1) IL316772A (cg-RX-API-DMAC7.html)
TW (1) TW202400627A (cg-RX-API-DMAC7.html)
WO (1) WO2023215840A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117551A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2021257480A2 (en) * 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods

Also Published As

Publication number Publication date
JP2025515091A (ja) 2025-05-13
AU2023265150A1 (en) 2024-11-14
CA3251504A1 (en) 2023-11-09
CN119698286A (zh) 2025-03-25
WO2023215840A1 (en) 2023-11-09
EP4518881A1 (en) 2025-03-12
IL316772A (en) 2025-01-01
US20250177482A1 (en) 2025-06-05
TW202400627A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
Duh et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth
KR101682240B1 (ko) Ace2 폴리펩티드
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
CN100528235C (zh) 红细胞生成素共轭物
US12116606B2 (en) Complement factor I-related compositions and methods
JP2002543837A (ja) 組換えセトマンナン結合性レクチン
CN103797115A (zh) 具有快速加工性能的经过修饰的酸性α葡糖苷酶
CN112384236A (zh) 用于治疗微血管血栓形成的靶向溶栓
US5359033A (en) Cleaved dimers of mullerian inhibiting substance-like polypeptides
JP2022548367A (ja) 眼科障害の処置または防止における使用のための薬剤
JPS63102699A (ja) 新規なdafの製造のための核酸
CN118804759A (zh) 补体因子i相关的组合物和方法
US9469679B2 (en) Neurturin molecules
US20250177482A1 (en) Complement factor i dosing regimens for treating ocular diseases
CN116675777A (zh) 包含补体抑制结构域的多特异性配体结合分子及其用途
JP2024543158A (ja) 多重特異性リガンド結合分子及びその用途
CN101155916A (zh) 作为血栓溶解剂的靶向性纤溶酶原激活物融合蛋白
US20040192589A1 (en) Production of high molecular mass lectins
EP2774935B1 (en) Improved neurturin molecules
CN116162148A (zh) 多特异性配体结合分子及其应用
US20220168434A1 (en) Application of transthyretin in entering eye and preparing drop
CA3147828C (en) Agent for use in treatment or prevention of ophthalmic disorders
US6329500B1 (en) Transforming growth factor-β binding site
CN116635528A (zh) 补体因子i相关组合物和方法
KR19980702956A (ko) 트롬보포이에틴(tpo)의 흡착방지방법 및 안정한 tpo 함유조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000